HEPION PHARMACEUTICALS, INC. Payments of Derivative Issuance Costs
HEPION PHARMACEUTICALS, INC. (HEPA) had Payments of Derivative Issuance Costs of $500.00 thousand as of 2023-10-03, per its 10-Q filed 2024-08-13.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfDerivativeIssuanceCosts · last filed 2024-08-13
- 2023-10-03: Payments of Derivative Issuance Costs $500.00K.
| Period end | Payments of Derivative Issuance Costs |
|---|---|
| 2023-10-03 | $500.00K 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |